Sanofi - American Depositary Shares (SNY)
SNY moved a median of +0.02% 30 minutes after news, and -0.06% by the close. How SNY actually reacts to news — the realized, point-in-time move the market made, measured across 798 labeled events over the last three years with zero look-ahead.
SNY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 50% | 798 |
| 30-min | +0.02% | 52% | 798 |
| 60-min | +0.02% | 52% | 798 |
| to close | -0.06% | 47% | 796 |
| Middle 50% of SNY reactions | -0.20% to +0.22% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 798 |
Half of all Sanofi - American Depositary Shares news events land between -0.20% and +0.22% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SNY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 37 | +0.04% | 54% | +0.19% |
| Analyst downgrades | 39 | +0.07% | 64% | -0.11% |
| Coverage initiations | 15 | +0.24% | 80% | -0.22% |
| Rating reiterations | 13 | -0.07% | 31% | -0.14% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how SNY ranks against every other measured name →
That’s how SNY usually reacts — get an email when it moves on news →Email me when SNY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SNY's baseline. Nothing else.
Recent SNY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Sanofi and pCPA Sign Letter of Intent for Dupixent® Across Four Indications in Dermatology and Respiratory Care | Press release | Canada Newswire | +0.10% | -0.04% | |
| Press Release : Availability of the aide-mémoire for Q3 2026 results | Press release | GlobeNewswire | -0.45% | -1.20% | |
| Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID® | Press release | PR Newswire | -0.07% | +0.22% | |
| Form 6-K Sanofi For: Oct 01 | SEC filing · Form 6-K | SEC EDGAR | -0.07% | -0.76% | |
| Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies | Press release | GlobeNewswire | -0.37% | -2.82% | |
| Form 6-K Sanofi For: Sep 17 | SEC filing · Form 6-K | SEC EDGAR | +0.28% | +0.75% | |
| Sanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investment | Press release | Canada Newswire | +0.00% | -0.22% | |
| Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines | Press release | GlobeNewswire | -0.43% | -0.85% | |
| Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™ | Press release | PR Newswire | +0.07% | -0.33% | |
| Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS® | Press release | PR Newswire | +0.09% | -0.77% | |
| Form N-PX Sanofi For: Jun 30 | SEC filing · Form N-PX | SEC EDGAR | -0.11% | +0.61% | |
| Form 6-K Sanofi For: Aug 06 | SEC filing · Form 6-K | SEC EDGAR | +0.16% | -0.95% | |
| Form 6-K Sanofi For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.92% | +2.02% | |
| Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded | Press release | GlobeNewswire | -0.92% | +2.02% | |
| Form 13F-HR Sanofi For: Jun 30 | SEC filing · Form 13F-HR | SEC EDGAR | +0.56% | +1.43% | |
| Form 6-K Sanofi For: Jul 27 | SEC filing · Form 6-K | SEC EDGAR | -0.29% | +0.62% | |
| Form 6-K Sanofi For: Jul 17 | SEC filing · Form 6-K | SEC EDGAR | +0.25% | +0.45% | |
| Form 6-K Sanofi For: Jul 07 | SEC filing · Form 6-K | SEC EDGAR | +0.09% | -0.44% | |
| Press Release: Availability of the aide-mémoire for Q2 2026 results | Press release | GlobeNewswire | -0.42% | -1.65% | |
| Form 11-K Sanofi For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | +0.00% | -0.46% | |
| Form NT 11-K Sanofi For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +0.08% | -0.50% | |
| Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study | Press release | GlobeNewswire | -0.42% | -0.97% | |
| Form 6-K Sanofi For: Jun 24 | SEC filing · Form 6-K | SEC EDGAR | -0.64% | -1.83% | |
| Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses | Press release | GlobeNewswire | +0.02% | -1.58% | |
| Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia | Press release | GlobeNewswire | +0.02% | -1.58% | |
| Form 6-K Sanofi For: Jun 22 | SEC filing · Form 6-K | SEC EDGAR | +0.04% | +2.13% | |
| Form 6-K Sanofi For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | +0.10% | -0.29% | |
| Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy | Press release | GlobeNewswire | +0.39% | +0.32% | |
| Form 6-K Sanofi For: Jun 08 | SEC filing · Form 6-K | SEC EDGAR | +0.23% | -1.19% | |
| Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector | Press release | GlobeNewswire | +0.23% | -1.19% | |
| Press Release: Sanofi launches 2026 global employee stock purchase plan | Press release | GlobeNewswire | +0.19% | +0.45% | |
| Form SD Sanofi | SEC filing · Form SD | SEC EDGAR | +0.22% | +0.86% | |
| Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease | Press release | GlobeNewswire | +0.22% | +0.86% | |
| Form 6-K Sanofi For: May 27 | SEC filing · Form 6-K | SEC EDGAR | -0.08% | -0.99% | |
| Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD | Press release | GlobeNewswire | +0.27% | +0.46% | |
| Form 13F-HR Sanofi For: Mar 31 | SEC filing · Form 13F-HR | SEC EDGAR | +0.07% | -0.90% | |
| Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 | Press release | PR Newswire | +0.07% | +0.09% | |
| Form 6-K Sanofi For: May 05 | SEC filing · Form 6-K | SEC EDGAR | -0.14% | +0.02% | |
| Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients | Press release | Canada Newswire | +0.10% | +0.17% | |
| Form 6-K Sanofi For: Apr 29 | SEC filing · Form 6-K | SEC EDGAR | +0.04% | +0.79% | |
| Form 6-K Sanofi For: Apr 27 | SEC filing · Form 6-K | SEC EDGAR | -0.02% | -0.46% | |
| Form 6-K Sanofi For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -0.14% | -1.84% | |
| Press Release: Q1 2026: double-digit sales and business EPS growth | Press release | GlobeNewswire | -0.14% | -1.84% | |
| Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US | Press release | GlobeNewswire | -0.27% | -1.32% | |
| Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study | Press release | GlobeNewswire | +0.10% | +0.06% | |
| Form 6-K Sanofi For: Apr 15 | SEC filing · Form 6-K | SEC EDGAR | +0.21% | -0.35% | |
| New Research Highlights Cas-CLOVER Gene Editing Potential for CHO Cell Line Development | Press release | PR Web | +0.10% | +0.35% | |
| Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria | Press release | GlobeNewswire | -0.43% | +1.32% | |
| Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians | Press release | Canada Newswire | -0.09% | +0.96% | |
| Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP | Press release | GlobeNewswire | -0.96% | -0.55% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SNY section they belong to.
Where else SNY is measured.
SNY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SYNERGY PHARMACEUTICALS (SGYP) | 803 | -0.38% | 41% |
| BioVie Inc. - Common stock (BIVI) | 798 | -0.84% | 36% |
| Cerecor, Inc (CERC) | 795 | -0.03% | 43% |
| Second Sight Medical Products, Inc. (EYES) | 788 | -0.56% | 34% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sanofi - American Depositary Shares's median reaction calculated?
Every labeled SNY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 798 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of SNY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SNY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.